Navigation Links
mPhase Technologies, Inc. Commencing Discussions with Major European Drug Company for Drug Delivery System

LITTLE FALLS, New Jersey, April 23, 2013 /PRNewswire/ --

mPhase Technologies, Inc. (OTCBB: XDSL) reported today that it has commenced the discussion of its drug delivery system with a major European Drug Company. The discussions were arranged through mPhase's  continuing relationship with Invest In France, an agency of the French government. The Drug Company is a member of the Grenoble Technology Cluster known as Minalogic ( The Cluster consists of government, corporate and educational members that are engaged in high technology research in the leading scientific disciplines such as micro- and nano-technologies and embedded systems on chips. Minalogic recently received the highest rating for cluster-management excellence from the European Union. (

The Company first visited the Cluster in March of 2012 after the relevant agencies reviewed mPhase's patent portfolio. mPhase is now actively continuing discussions with potential large strategic partners seeking to use the Company's Smart Surface intellectual property. It is anticipated that upon the establishment of such a strategic partnership, research would continue at one of the Cluster's laboratory facilities at Grenoble, France.  The partnership would include a strategic sponsoring partner that would provide funding and target and custom tailor mPhase's Smart Surface Technology to be used in a commercial product. All potential strategic partners are currently members of the Cluster.

The scientific focus and interest is based upon the ability of mPhase's Smart Surface technology to electronically control the precise flow of a fluid on a nano-structured surface. The technology has the potential capability of delivering controlled dosages of drugs needed and prescribed for an individual.

About mPhase Technologies, Inc.

mPhase Technologies is a leading nanotechnology innovator in Smart Surfaces. Potential applications include energy storage systems, drug delivery systems, self-cleaning systems, liquid and chemical sensor systems, and filtration systems. mPhase has pioneered its first Smart Surface enabled product, the mPhase Smart NanoBattery.

In addition to the Smart Surface technology, mPhase, in collaboration with Porsche Design Studio, has developed a world class automotive jump starter. See  More information about the company can be found at

Forward-Looking Statements

As a cautionary note to investors, certain matters discussed in this press release may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such matters involve risks and uncertainties that may cause actual results to differ materially, including the following: changes in economic conditions; general competitive factors; acceptance of the Company's products in the market; the Company's success in technology and product development; the Company's ability to execute its business model and strategic plans; and all the risks and related information described from time to time in the Company's SEC filings, including the financial statements and related information contained in the Company's SEC Filing. mPhase assumes no obligation to update the information in this release.

mPhase Technologies, Inc.

SOURCE mPhase Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
3. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
4. Senesco Technologies, Inc. to Webcast, Live, at on December 1st
5. Animal Biotechnology - Technologies, Markets and Companies
6. Gene Therapy - Technologies, Markets and Companies
7. Biomarkers - Technologies, Markets and Companies
8. Senesco Technologies, Inc. Investor Presentation Now Available for On-demand Viewing at
9. Cytogenetics - Technologies, Markets and Companies
10. Cell Therapy - Technologies, Markets and Companies
11. Palatin Technologies, Inc. to Present at the 24th Annual ROTH OC Growth Stock Conference
Post Your Comments:
(Date:11/30/2015)... - BioAmber Inc. (NYSE: BIOA ), a leader in renewable ... Act on Climate Pledge, alongside more than 140 companies from ... Administration to demonstrate an ongoing commitment to climate action and ... Paris climate negotiations. ... . --> BioAmber uses biotechnology to convert ...
(Date:11/30/2015)... , Nov. 30, 2015 Harvard ... ), a biotechnology company developing bioengineered organ implants ... written notification from The NASDAQ Stock Market that ... price requirements. The letter noted that as a ... common stock having exceeded $1.00 per share for ...
(Date:11/30/2015)... GA (PRWEB) , ... November 30, 2015 , ... ... a new globally touring exhibition Jurassic World: The Exhibition, opening in March 2016 ... will embark on a worldwide tour including several North American tour dates. The ...
(Date:11/30/2015)... 30, 2015 TapImmune, Inc. ... of innovative peptide and gene-based immunotherapeutics and vaccines for ... it will be presenting at the 8 th ... at 2.30 PM PT. Dr. John N. Bonfiglio ... be giving the presentation and will join TapImmune management ...
Breaking Biology Technology:
(Date:11/16/2015)... Nov 16, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced expansion of its TDDI product ... touch controller and display driver integration (TDDI) solutions ... These new TDDI products add to the previously-announced ... TD4302 (WQHD resolution), and TD4322 (FHD resolution) solutions. ...
(Date:11/10/2015)... , Nov. 10, 2015  In this ... the basis of product, type, application, disease ... in this report are consumables, services, software. ... are safety biomarkers, efficacy biomarkers, and validation ... report are diagnostics development, drug discovery and ...
(Date:11/2/2015)...  SRI International has been awarded a contract of ... to the National Cancer Institute (NCI) PREVENT Cancer Program ... modern testing and support facilities, and analytical instrumentation to ... studies to evaluate potential cancer prevention drugs. ... Drug Development Program is an NCI-supported pipeline to bring ...
Breaking Biology News(10 mins):